-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Axcella Health (NASDAQ:AXLA) and Icosavax (NASDAQ:ICVX) Critical Review
Axcella Health (NASDAQ:AXLA) and Icosavax (NASDAQ:ICVX) Critical Review
Axcella Health (NASDAQ:AXLA – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Profitability
This table compares Axcella Health and Icosavax's net margins, return on equity and return on assets.
Get Axcella Health alerts:Net Margins | Return on Equity | Return on Assets | |
Axcella Health | N/A | -305.29% | -120.62% |
Icosavax | -1,326.23% | -36.82% | -35.11% |
Earnings and Valuation
This table compares Axcella Health and Icosavax's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Axcella Health | N/A | N/A | -$64.63 million | ($1.73) | -0.94 |
Icosavax | $7.80 million | 16.41 | -$66.97 million | ($2.93) | -1.10 |
Analyst Recommendations
This is a breakdown of recent recommendations for Axcella Health and Icosavax, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Axcella Health | 0 | 0 | 5 | 0 | 3.00 |
Icosavax | 0 | 0 | 1 | 0 | 3.00 |
Axcella Health currently has a consensus price target of $6.80, suggesting a potential upside of 319.75%. Icosavax has a consensus price target of $18.00, suggesting a potential upside of 460.75%. Given Icosavax's higher possible upside, analysts clearly believe Icosavax is more favorable than Axcella Health.
Institutional & Insider Ownership
64.8% of Axcella Health shares are owned by institutional investors. Comparatively, 82.4% of Icosavax shares are owned by institutional investors. 6.5% of Axcella Health shares are owned by insiders. Comparatively, 39.1% of Icosavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Axcella Health has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Icosavax has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Summary
Icosavax beats Axcella Health on 7 of the 12 factors compared between the two stocks.
About Axcella Health
(Get Rating)
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
About Icosavax
(Get Rating)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.
Axcella Health (NASDAQ:AXLA – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
安赛乐健康(纳斯达克:AXLA-GET评级)和艾科萨瓦克斯(纳斯达克:ICVX-GET评级)都是小盘医疗公司,但哪只股票更优越?我们将根据这两家公司的盈利能力、机构所有权、风险、估值、分析师建议、股息和收益等方面的实力进行比较。
Profitability
盈利能力
This table compares Axcella Health and Icosavax's net margins, return on equity and return on assets.
此表比较了Axcella Health和ICosavax的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Axcella Health | N/A | -305.29% | -120.62% |
Icosavax | -1,326.23% | -36.82% | -35.11% |
净利润率 | 股本回报率 | 资产回报率 | |
AXCELA健康 | 不适用 | -305.29% | -120.62% |
伊科萨克斯 | -1,326.23% | -36.82% | -35.11% |
Earnings and Valuation
收益和估值
This table compares Axcella Health and Icosavax's top-line revenue, earnings per share and valuation.
这张表格比较了Axcella Health和ICosavax的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Axcella Health | N/A | N/A | -$64.63 million | ($1.73) | -0.94 |
Icosavax | $7.80 million | 16.41 | -$66.97 million | ($2.93) | -1.10 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
AXCELA健康 | 不适用 | 不适用 | -6,463万元 | ($1.73) | -0.94 |
伊科萨克斯 | 780万美元 | 16.41 | -6,697万元 | ($2.93) | -1.10 |
Analyst Recommendations
分析师建议
This is a breakdown of recent recommendations for Axcella Health and Icosavax, as reported by MarketBeat.
这是MarketBeat报道的最近对Axcella Health和ICosavax的建议的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Axcella Health | 0 | 0 | 5 | 0 | 3.00 |
Icosavax | 0 | 0 | 1 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
AXCELA健康 | 0 | 0 | 5 | 0 | 3.00 |
伊科萨克斯 | 0 | 0 | 1 | 0 | 3.00 |
Axcella Health currently has a consensus price target of $6.80, suggesting a potential upside of 319.75%. Icosavax has a consensus price target of $18.00, suggesting a potential upside of 460.75%. Given Icosavax's higher possible upside, analysts clearly believe Icosavax is more favorable than Axcella Health.
Axcell a Health目前的共识目标价为6.8美元,这意味着潜在的上涨幅度为319.75。Icoavax的普遍目标价为18美元,暗示潜在上涨460.75%。考虑到ICosavax更有可能的上行空间,分析师们显然认为ICosavax比Axcella Health更有利。
Institutional & Insider Ownership
机构与内部人持股
64.8% of Axcella Health shares are owned by institutional investors. Comparatively, 82.4% of Icosavax shares are owned by institutional investors. 6.5% of Axcella Health shares are owned by insiders. Comparatively, 39.1% of Icosavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Axcell a Health 64.8%的股份由机构投资者持有。相比之下,Icoavax 82.4%的股份由机构投资者持有。Axcell a Health 6.5%的股份由内部人士持有。相比之下,Icoavax 39.1%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一只股票有望实现长期增长。
Volatility and Risk
波动性和风险
Axcella Health has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Icosavax has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Axcell a Health的贝塔系数为1.1,表明其股价的波动性比标准普尔500指数高出10%。相比之下,ICosavax的贝塔系数为1.33,这表明其股价的波动性比标准普尔500指数高出33%。
Summary
摘要
Icosavax beats Axcella Health on 7 of the 12 factors compared between the two stocks.
在比较两只股票的12项指标中,ICosavax有7项超过了Axcella Health。
About Axcella Health
关于Axcella Health
(Get Rating)
(获取评级)
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Axcella Health Inc.在美国以临床阶段生物技术公司的身份运营。该公司使用内源性代谢调节剂组合物治疗复杂疾病并增强健康。它的主要候选产品包括AXA1665,它正处于降低临床肝性脑病复发风险的第二阶段临床试验;以及AXA1125,它正处于治疗非酒精性脂肪性肝炎的2b阶段临床试验,以及针对患者的长期COVID治疗的2a阶段临床试验。该公司前身为Newco LS16,Inc.,并于2016年6月更名为Axcell a Health Inc.。Axcell a Health Inc.成立于2008年,总部设在马萨诸塞州剑桥市。
About Icosavax
关于ICosavax
(Get Rating)
(获取评级)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
ICosavax,Inc.是一家生物制药公司,开发针对传染病的疫苗。该公司在其病毒样颗粒(VLP)平台技术的帮助下,主要专注于威胁生命的呼吸道疾病。该公司正在筹备的产品包括IVX-121,一种以RSV为靶标的候选疫苗,正处于1/1b期临床试验;IVX-A12,一种具有RSV/人偏肺病毒(HMPV)二价靶标的呼吸道合胞病毒(RSV)单价抗原候选;IVX-241,一种以hMPV为靶标的疫苗候选;以及IVX-411,一种具有SARS-CoV-2靶标的原始受体结合结构域(RBD)序列抗原,正处于1/2期临床试验。该公司成立于2017年,总部位于华盛顿州西雅图。
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Axcell健康日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Axcella Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧